Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Degenerative Disc Disease, Spondylolisthesis, Retrolisthesis
Interventions
Surgery with the Keos Lumbar Interbody Fusion Device
Device
Lead sponsor
Invibio Ltd
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Conditions
Degenerative Disc Disease
Interventions
One-level or two-level anterior lumbar interbody fusion, InQu Bone Graft Extender and Substitute mixed with BMAC, Synthes Spinal Instrumentation
Procedure · Biological · Device
Lead sponsor
Kansas Joint and Spine Institute
Network
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Wichita, Kansas
Conditions
Friedreich Ataxia
Interventions
CTI-1601, Placebo
Biological
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Conditions
Degenerative Disc Disease
Interventions
Natural Matrix Protein (NMP)
Biological
Lead sponsor
Induce Biologics USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Shreveport, Louisiana
Active, not recruiting No phase listed Observational

Artoss Prospective Spine Registry Outcomes

NCT04439032
Conditions
Spinal Fusion
Interventions
NanoBone Bone Graft Substitute
Other
Lead sponsor
Artoss Inc.
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Timeline
2020 – 2025
U.S. locations
6
States / cities
Chandler, Arizona • Tempe, Arizona • San Diego, California + 3 more
Conditions
Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Spondylolisthesis, Lumbar Spondylosis, Lumbar Radiculopathy, Lumbar Spine Instability, Synovial Cyst, Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Intervertebral Discs
Interventions
Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine, normal saline
Drug
Lead sponsor
John O'Toole
Other
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting Not applicable Interventional

Interposed Nucleus aDBS for Ataxia

NCT07325487
Conditions
Spinocerebellar Ataxia (SCA), Spinocerebellar Ataxia Type 6
Interventions
Deep Brain Stimulation
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
Interventions
Standard analgesia use [Oxygen], Standard analgesia use [Hydromorphone], Standard analgesia use [Volatile Anesthesia], Standard analgesia use [Fentanyl], Multi-modal pain management [Acetaminophen + Gabapentin], Multi-modal pain management [Fentanyl], Multi-modal pain management [Intravenous Ketamine], Multi-modal pain management [Valium + Gabapentin]
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Friedreich's Ataxia
Interventions
RT001, Placebo
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
12 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Gainesville, Florida + 3 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Degenerative Disc Disease, Disc Herniation
Interventions
SeaSpine Shoreline
Device
Lead sponsor
Research Source
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Southfield, Michigan
Conditions
Cervical Spondylosis With Myelopathy, Cervical Radiculopathy, Cervical Disc Herniation, Degenerative Disc Disease
Interventions
Cervical arthroplasty, Semi-Constrained Nuvasive Simplify, Unconstrained Biomet Zimmer Mobi-C
Procedure · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Completed No phase listed Observational Accepts healthy volunteers

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

NCT02365922
Conditions
FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD), PPA Syndrome, Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis (ALS), Oligosymptomatic PSP (oPSP), Corticobasal Syndrome (CBS)
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
1,489 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype & Biomarkers in ALS and Related Disorders

NCT02327845
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Progressive Muscular Atrophy, Multisystem Proteinopathy
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
708 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2031
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 10 more
Conditions
High Tumor Mutation Burden, High TMB (Tumor Mutation Burden), MSS (Microsatellite Stable)
Interventions
MK-3475
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Columbus, Ohio
Conditions
Lumbar Spondylolisthesis, Lumbar Spine Degeneration
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Friedreich Ataxia
Interventions
Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg
Drug
Lead sponsor
Biogen
Industry
Eligibility
16 Years to 40 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more
Conditions
Friedreich's Ataxia
Interventions
Idebenone, Placebo
Drug
Lead sponsor
Santhera Pharmaceuticals
Industry
Eligibility
8 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California • Philadelphia, Pennsylvania
Conditions
Degenerative Disc Disease
Interventions
Osteocel Plus
Biological
Lead sponsor
NuVasive
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 71 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Conditions
Prolapsed Lumbar Disc, Prolapsed Cervical Disc, Intervertebral Disc Degeneration, Spondylolisthesis, Grade 1, Intervertebral Disc Displacement
Interventions
Not listed
Lead sponsor
Wenzel Spine
Industry
Eligibility
18 Years to 99 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas
Conditions
Lumbar Degenerative Disc Disease
Interventions
AlterG
Other
Lead sponsor
Justin Parker Neurological Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boulder, Colorado
Completed No phase listed Observational

Fusion Assessment Clinical Trial

NCT00736398
Conditions
Degenerative Disc Disease
Interventions
Spinal fusion
Procedure
Lead sponsor
Flexuspine, Inc.
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
6
States / cities
Clearwater, Florida • Temple Terrace, Florida • Baltimore, Maryland + 3 more
Conditions
Lumbar Degenerative Disc Disease, Lower Back Pain, Chronic Lower Back Pain
Interventions
Not listed
Lead sponsor
The Foundation for Spinal Research, Education and Humanitarian Care, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Odessa, Florida